Ruti Aga's Six-Year Ban: Two Years for the Drug, Four for a Prescription That Never Existed

The AIU statement that landed on Thursday is, before anything else, an arithmetic document. Six years. Break the number and it splits cleanly: two years for the substance found in her sample, four years for the piece of paper that was supposed to explain it. At sixty-two I still keep the habit I kept at twenty-seven — add first, comment later. And the addition leaves one conclusion standing: Ruti Aga's six-year ban was not bought with a drug. It was bought with a prescription.

The prescription fails three separate verifications. The clinic that supposedly issued it did not exist. The person who wrote it was a family member with no medical registration. And when questioned, that person claimed to have used "an old prescription pad from a former workplace" — a workplace the clinic itself disowned in plain words. Three independent checks, three failures.

This report is not about the race in March. The source does not carry that race's time, its field, or its splits. It is about how a thirty-two-year-old marathoner whose record includes a World Marathon Major title and three Major runner-up finishes ended her career not with a chemical but with a document — and how that document proved more damaging than the drug it was built to conceal.

Here I go back to the oldest discipline in my ledger: one column for what happened; one for what we wished had. The first column gets only what the statement, the Code and the paperwork say. The second gets everything the federation, the sponsor and the nostalgia industry wanted to be true. The gap between them is the story.

Context: a Major winner and a March race with no mark

Aga is Ethiopian, thirty-two. The biggest line against her name is the 2026 Tokyo Marathon, a World Marathon Major title in roughly 2:20:40. Before that, second at Berlin 2026 in about 2:18:34. Three Major second places in all. Those figures come out of my register and I flag them as I have flagged them for forty years — verification pending, because the AIU statement gives no personal best, no split, no season's best.

What the statement does give: a half marathon in China this March, which she won. A sample collected there. Methylprednisolone in it. Provisional suspension from 10 September, and a six-year ban counted from the same 10 September. Statement issued on a Thursday.

Now the technical correction that is also the legal hinge of the whole case, and which early reporting got wrong. Methylprednisolone was described as a "prohibited steroid" and as classed performance-enhancing by WADA. That is imprecise. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid, which is S1. And S9 substances are prohibited in-competition only, by injection, oral or rectal route. A therapeutic knee injection given out-of-competition is entirely lawful. It becomes a violation only when residues are present in an in-competition sample.

The consequence is blunt: this case was never a fight about "steroid use." It was a fight about route and timing — which route, on which date, how many days before the gun. A road race's testing window opens at 23:59 the night before, so an injection given days earlier can be caught. That is exactly where the defence had a door. And that is exactly where she closed it herself.

Core: how six years is assembled

Read the architecture, because the architecture is the news. Two years for the presence violation — the standard sanction for a substance the Code classes as a Specified Substance where intent is not established. Then four years for tampering — the Code's standard tampering sanction. Two plus four, six. The arithmetic is internally consistent. And consistent arithmetic says one more thing: the panel rejected the no-significant-fault mitigation that would otherwise have cut the presence sanction. This was not accepted as a mistake.

And here the paradox appears, the one anti-doping commentary usually skips: a forged document is itself circumstantial evidence of concealment intent. Yet in this case the forgery did not aggravate the presence sanction — it attached as a separate, independent charge worth four years. Which is why the total is two years for the drug and four for the paper. In this case the paper cost twice what the drug did.

Now the defence that existed and was destroyed. Glucocorticoids have no proven benefit to endurance performance; they are used to suppress pain and inflammation, not to go faster. Intra-articular methylprednisolone for knee synovitis is standard sports medicine in distance runners. A lawful path was therefore available: genuine medical records, a TUE held or applied for, and a clear account of route and timing. Had all three existed, the case could have been argued at the no-fault end of the presence charge — possibly a reprimand or a heavily reduced period, and no tampering charge at all.

So it is inaccurate to say she lost her career to a drug. She lost it because when a defence existed on paper, she replaced the paper — and the paper was false. Medical plausibility turned out to be legally fatal, and that is the hardest lesson in the file.

This is where Anju Bobby George's habit comes back to me, the one I witnessed in Paris in 2026: she wrote down every attempt, including the ones that embarrassed her. Six real attempts, six real documents that save you. Which gives me the sharpest line in this piece — what was missing from Aga's file was not the drug. It was the paper. And when real paper is absent, people manufacture paper. That is not a moral gap. It is an administrative one.

Then the medical governance, because it is the largest evidence of the underlying failure. The "doctor" was a relative, unregistered. No team physician appears. No TUE infrastructure appears. That is not a filing error; it is the signature of an athlete operating without credentialed medical support. Across Ethiopian and Kenyan road-running entourages this is not an exception — the same club-agent-altitude system that produces the deepest talent pool in the world is thin at exactly the medical layer. The gap runs both ways.

It is not only their gap. In fifty years I have watched small units from the Patiala camps to the Railway trials, and the rule there is identical: where documents do not exist, documents get made in the name of order. The difference is economic. An Indian athlete's professional economy runs on a job — Railways, Services, state police, TOPS since 2026 — and an East African road runner's runs on appearance fees. In the second system the incentive to mask pain is far more direct.

Core: China's label circuit and two economies colliding

Here the case says its least-reported thing. The March race was in China and the source does not name it, but the inference is clean: if an AIU sample exists, it was a World Athletics Label road race with an elite women's field and a testing protocol. What level she ran at we do not know, because no mark is given. Drawing form from the win would be inference, and inference belongs in my second column, not the first.

What does follow is structural: the Chinese label circuit has become an attractive, low-risk income tier for East African marathoners between Majors — large appearance fees, deep elite fields, low prestige exposure. And that same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same race, and where two economies meet on one course, the catch rate rises.

There is a second edge to that collision. Large appearance fees mean multiple continents in twelve months, and marathon load accumulates in knees, Achilles and calves. Once that load becomes injury, the cheapest and most available fix is a glucocorticoid — it reduces swelling, dampens pain, and therefore protects the next fee. That is why S9 cases cluster in road running rather than sprints. In my ledger this is not one runner's lapse but a design flaw in an industry where the treatment of injury and the protection of income arrive through the same needle.

Core: valuing the career, because six years is not a number but an age

Thirty-two plus six is thirty-eight. That is the age at which she may race again, if an appeal changes nothing. Returning at thirty-eight into Ethiopian women's marathon depth is a selection impossibility, because a 2:18 performer there is not automatically picked. The national capacity takes no measurable hit — her three Major second places were commercial-tier results, not championship medals. Ethiopia's medal arithmetic stays as it was.

What survives is the record, and even that with conditions. The 2026 Tokyo title and three Major second places stand unless earlier use is established. The source does not state the disqualification scope — and where the source is silent, I stay silent. But standard practice is clear: the competition at which the sample was collected is normally disqualified, result and prize money. Which puts the March win, its fee and any ranking points accrued after it on the forfeiture list.

Commercially, distance-running sponsorship was already thin. A six-year ban does not make it zero; it makes it negative. This is where an old market habit of mine applies — the market lies politely; the ledger does not. A sponsor's release will say "temporarily withdrawn." The paper says six years.

Core: the classification error that distorts the debate

The reporting called it a steroid. The damage is that readers now compare this file to cases involving anabolic steroids, testosterone or blood doping, where intent and benefit are both legible. Here neither is. An S9 case is technically a timing question, not a moral one: which route, which date, which testing window. A reporter who erases that distinction stops the reader from learning that a defence existed — and if a defence existed, the bitterness of the sanction has a different cause.

I learned that lesson forty-five years ago, in the paperwork. The class of a substance matters more than its name; its route and timing matter more than its class. The Seiko never lied to me, so I tried never to lie to it — but a watch gives you time, not cause. The class tells you what the rule says; it does not tell you what anyone thought.

Contrarian: six years for a drug with no proven endurance benefit

Now the question the AIU statement does not ask and East African road-running communities ask constantly. A substance with no established aerobic benefit, found as residue, costs two years. A forged prescription in the same file costs four. Six in total. Is the proportion right?

My answer comes in two parts and I keep them apart, because merging them corrupts the argument. First: two years for the presence violation is standard under the Code, and questioning it is rule debate, not rule breaking. Second: four years for tampering is also standard, because tampering is treated as the larger offence — for a simple reason. Tampering attacks the entire investigative system, not merely your own blood. What is uncomfortable is that when the two standards land on one person, the outcome is functionally a lifetime ban — and the word "lifetime" appears nowhere in the Code.

This is where I have to fight my own habit. Some will argue the AIU is harsh on African road runners. I raise that claim carefully, because correlation is not causation. The group with the most label races gets the most tests; where there are the most tests, the most will be caught. That is counting, not proof of bias. The real question is not who was caught but who, at which level, is not being caught — and no press release answers that.

And here is what stings most, because it is my own profession's failure. The change in this case is not that an athlete was caught. The change is that the enforcement frontier has moved from detection to document verification. When a regulator starts confirming whether a clinic exists, anti-doping has entered a second phase — and that phase is most dangerous for the community where real clinics are scarce. Protocol is what we agreed to while we were still calm. Nobody was calm while that prescription was being written.

Which is the least-written truth here: the problem is not that the rules are strict. The problem is that the rules are being enforced in a place the system never reached — and where the system never reached, an athlete asks her family for help, not her federation.

I keep a third column too, unpublished but always checked: what improved, by how much, on what date. Three things improved here and deserve the same rigour as the sanction. One: testing density in China's label circuit has risen, because samples now exist. Two: the AIU has established document verification as an independent charge, and the four-year figure will act as a deterrent in future files. Three: the statement clarified something previously blurred — the weight of a sanction falls on the explanation, not the substance. That is not good news. It is the most useful news.

What the source did not say is also part of the record

Blank space belongs in a ledger. The blanks here are worth counting because they are not someone else's error; they are the limits of the reporting. No name, no time, no field quality for the March race. The ban's end year follows from the arithmetic (six years from 10 September) but is not stated in words. The disqualification scope is unstated. No statement from the Ethiopian federation — only the AIU speaks. No mention of the appeal window, though standard practice allows about twenty-one days from the reasoned decision to file with CAS. Most importantly, the athlete's own account exists in the statement only as far as the knee injury and the prescription; beyond that, nothing.

I will also record, per habit, that what is being described as "the panel found" sits in my hands as the language of a press release, not the pages of a reasoned decision. The story changes on page forty-one; I have found that from Anju's attempt sheet in 2026 to the CAS orders of 2026. So this is an interpretation of a statement, not of a judgment. The distinction is not small.

Forward signal

Three dates matter in this file and none of them belongs to a race. 10 September, from which the ban counts. The March race, whose result is heading for annulment. And a date that has not arrived — when the next road race takes a sample from an athlete surrounded by five informal medical hands and zero registered physicians.

My expectation is that more cases will come out of the same cluster, because the same informal network serves several athletes in one training group, and once enforcement moves to documents, the first caught are those already in the habit of making them. That is not prophecy; it is pattern, and I keep it in the verification-pending box.

The remaining question is the one I wrote into my register in Seoul in 2026 and have never answered: do we punish an athlete for her error, or for a system we never built around her? Whether Aga returns at thirty-eight is the second question. The first is whether the next thirty-two-year-old marathoner whose knee gives way will have a registered physician, or an old prescription pad.